Fieger Ethan I, Fadel Kristen M, Modarres Amir H, Wickham Edmond P, Wolver Susan E
AACE Clin Case Rep. 2020 Aug 6;6(6):e330-e333. doi: 10.4158/ACCR-2020-0314. eCollection 2020 Nov-Dec.
We report a case of a successful reimplementation of a very low carbohydrate ketogenic diet (VLCKD) after a case of euglycemic diabetic ketoacidosis (euDKA).
A 42-year-old female with a history of type 2 diabetes mellitus on a self-administered VLCKD was prescribed a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Two weeks after initiation, she presented with nausea and vomiting and was found to be in euDKA which was treated with fluid resuscitation, insulin infusion, and cessation of the SGLT2 inhibitor. She was discharged on insulin and instructed not to resume a VLCKD.
After discharge, the patient experienced rapid weight gain and deteriorating glycemic control and desired to resume a VLCKD. She was referred to a university-based medical weight loss clinic that specializes in a VLCKD. The patient was monitored with daily contact via the electronic health record's patient portal and serial laboratory testing while her carbohydrate intake was slowly reduced and her insulin titrated off. She has safely remained in ketosis for 2 years without a further episode of euDKA.
As the clinical use of SGLT2 inhibitors and the VLCKD both become increasingly common, it is vital for practitioners to be aware that the combination can lead to euDKA. We present a case of successfully resuming a VLCKD after recovering from euDKA and cessation of SGLT2 inhibitor therapy.
我们报告一例在正常血糖性糖尿病酮症酸中毒(euDKA)病例后成功重新实施极低碳水化合物生酮饮食(VLCKD)的案例。
一名42岁患有2型糖尿病且自行采用VLCKD饮食的女性患者,开始服用钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂。开始用药两周后,她出现恶心和呕吐症状,被诊断为euDKA,接受了液体复苏、胰岛素输注治疗,并停用了SGLT2抑制剂。她出院时使用胰岛素,并被指示不要再恢复VLCKD饮食。
出院后,患者体重迅速增加,血糖控制恶化,她希望恢复VLCKD饮食。她被转诊至一家专门从事VLCKD饮食治疗的大学医学减重诊所。通过电子健康记录的患者门户进行每日联系,并进行系列实验室检测对患者进行监测,同时缓慢减少她的碳水化合物摄入量,并逐渐停用胰岛素。她已安全维持酮症状态两年,未再次发生euDKA。
随着SGLT2抑制剂和VLCKD饮食在临床上的使用都越来越普遍,从业者必须意识到两者联合使用可能导致euDKA。我们呈现了一例在从euDKA恢复并停止SGLT2抑制剂治疗后成功恢复VLCKD饮食的案例。